Medarex/Bristol Myers Squibbs’ Ipilimumab Shows Off Long-Term Survival Data At ASCO
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from a separate Phase II combination study also add to hopes for a positive outcome in the ongoing Phase III.
You may also be interested in...
Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise
During Bristol-Myers Squibb's investor day March 4, management's enthusiasm for an important late-stage drug in development for metastatic melanoma, ipilimumab, was palpable. CEO designate Lamberto Andreotti told the room full of analysts and investors that ipilimumab "has the potential to become a paradigm changer in the emerging field of immuno-oncology.
Bristol's Immuno-Oncology Leadership Stake Lies In Ipilimumab's Promise
During Bristol-Myers Squibb's investor day March 4, management's enthusiasm for an important late-stage drug in development for metastatic melanoma, ipilimumab, was palpable. CEO designate Lamberto Andreotti told the room full of analysts and investors that ipilimumab "has the potential to become a paradigm changer in the emerging field of immuno-oncology.
What Medarex Has To Offer At $2.4 Billion
Bristol-Myers Squibb's July 22 offer to buy Medarex for $2.4 billion seems to be a coup for the biotech. While most biotechs are struggling to raise money, Medarex enticed a suitor to pay nearly double its recent stock price